Cargando…
Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study)
INTRODUCTION: Observational studies have demonstrated an association between vitamin D deficiency and increased risk of morbidity and mortality in critically ill patients. Cohort studies and pilot trials have suggested promising beneficial effects of vitamin D replacement in the critical ill, at lea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858186/ https://www.ncbi.nlm.nih.gov/pubmed/31722941 http://dx.doi.org/10.1136/bmjopen-2019-031083 |
_version_ | 1783470902152790016 |
---|---|
author | Amrein, Karin Parekh, Dhruv Westphal, Sabine Preiser, Jean-Charles Berghold, Andrea Riedl, Regina Eller, Philipp Schellongowski, Peter Thickett, David Meybohm, Patrick |
author_facet | Amrein, Karin Parekh, Dhruv Westphal, Sabine Preiser, Jean-Charles Berghold, Andrea Riedl, Regina Eller, Philipp Schellongowski, Peter Thickett, David Meybohm, Patrick |
author_sort | Amrein, Karin |
collection | PubMed |
description | INTRODUCTION: Observational studies have demonstrated an association between vitamin D deficiency and increased risk of morbidity and mortality in critically ill patients. Cohort studies and pilot trials have suggested promising beneficial effects of vitamin D replacement in the critical ill, at least in patients with severe vitamin D deficiency. As vitamin D is a simple, low-cost and safe intervention, it has potential to improve survival in critically ill patients. METHODS AND ANALYSIS: In this randomised, placebo-controlled, double-blind, multicentre, international trial, 2400 adult patients with severe vitamin D deficiency (25-hydroxyvitamin D≤12 ng/mL) will be randomised in a 1:1 ratio by www.randomizer.at to receive a loading dose of 540 000 IU cholecalciferol within 72 hours after intensive care unit (ICU) admission, followed by 4000 IU daily for 90 days or placebo. Hypercalcaemia may occur as a side effect, but is monitored by regular checks of the calcium level. The primary outcome is all-cause mortality at 28 days after randomisation. Secondary outcomes are: ICU, hospital, 90-day and 1-year mortality; hospital and ICU length of stay, change in organ dysfunction on day 5 as measured by Sequential Organ Function Assessment (SOFA) score, number of organ failures; hospital and ICU readmission until day 90; discharge destination, self-reported infections requiring antibiotics until day 90 and health-related quality of life. Recruitment status is ongoing. ETHICS AND DISSEMINATION: National ethical approval was obtained by the Ethics Committee of the University of Graz for Austria, Erasme University Brussels (Belgium) and University Hospital Frankfurt (Germany), and will further be gained according to individual national processes. On completion, results will be published in a peer-reviewed scientific journal. The study findings will be presented at national and international meetings with abstracts online. TRIAL REGISTRATION: NCT03188796, EudraCT-No: 2016-002460-13. |
format | Online Article Text |
id | pubmed-6858186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-68581862019-12-03 Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) Amrein, Karin Parekh, Dhruv Westphal, Sabine Preiser, Jean-Charles Berghold, Andrea Riedl, Regina Eller, Philipp Schellongowski, Peter Thickett, David Meybohm, Patrick BMJ Open Intensive Care INTRODUCTION: Observational studies have demonstrated an association between vitamin D deficiency and increased risk of morbidity and mortality in critically ill patients. Cohort studies and pilot trials have suggested promising beneficial effects of vitamin D replacement in the critical ill, at least in patients with severe vitamin D deficiency. As vitamin D is a simple, low-cost and safe intervention, it has potential to improve survival in critically ill patients. METHODS AND ANALYSIS: In this randomised, placebo-controlled, double-blind, multicentre, international trial, 2400 adult patients with severe vitamin D deficiency (25-hydroxyvitamin D≤12 ng/mL) will be randomised in a 1:1 ratio by www.randomizer.at to receive a loading dose of 540 000 IU cholecalciferol within 72 hours after intensive care unit (ICU) admission, followed by 4000 IU daily for 90 days or placebo. Hypercalcaemia may occur as a side effect, but is monitored by regular checks of the calcium level. The primary outcome is all-cause mortality at 28 days after randomisation. Secondary outcomes are: ICU, hospital, 90-day and 1-year mortality; hospital and ICU length of stay, change in organ dysfunction on day 5 as measured by Sequential Organ Function Assessment (SOFA) score, number of organ failures; hospital and ICU readmission until day 90; discharge destination, self-reported infections requiring antibiotics until day 90 and health-related quality of life. Recruitment status is ongoing. ETHICS AND DISSEMINATION: National ethical approval was obtained by the Ethics Committee of the University of Graz for Austria, Erasme University Brussels (Belgium) and University Hospital Frankfurt (Germany), and will further be gained according to individual national processes. On completion, results will be published in a peer-reviewed scientific journal. The study findings will be presented at national and international meetings with abstracts online. TRIAL REGISTRATION: NCT03188796, EudraCT-No: 2016-002460-13. BMJ Publishing Group 2019-11-12 /pmc/articles/PMC6858186/ /pubmed/31722941 http://dx.doi.org/10.1136/bmjopen-2019-031083 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Intensive Care Amrein, Karin Parekh, Dhruv Westphal, Sabine Preiser, Jean-Charles Berghold, Andrea Riedl, Regina Eller, Philipp Schellongowski, Peter Thickett, David Meybohm, Patrick Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title | Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title_full | Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title_fullStr | Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title_full_unstemmed | Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title_short | Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study) |
title_sort | effect of high-dose vitamin d3 on 28-day mortality in adult critically ill patients with severe vitamin d deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase iii rct (the vitdalize study) |
topic | Intensive Care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858186/ https://www.ncbi.nlm.nih.gov/pubmed/31722941 http://dx.doi.org/10.1136/bmjopen-2019-031083 |
work_keys_str_mv | AT amreinkarin effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT parekhdhruv effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT westphalsabine effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT preiserjeancharles effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT bergholdandrea effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT riedlregina effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT ellerphilipp effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT schellongowskipeter effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT thickettdavid effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT meybohmpatrick effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy AT effectofhighdosevitamind3on28daymortalityinadultcriticallyillpatientswithseverevitaminddeficiencyastudyprotocolofamulticentreplacebocontrolleddoubleblindphaseiiirctthevitdalizestudy |